Financial News Feed

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Read more

ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump....

Read more

No summary available....

Read more

https://www.investing.com/analysis/abiomed-abmd-to-launch-impella-cp-with-smartassist-at-scai-200422971...

Read more

ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients....

Read more

The FDA approves the use of Abiomed's ([[ABMD]] -3.6%) Impella 5.0 and Impella LD heart pumps for the treatment of cardiogenic shock for up to 14 days (fro...

Read more

ABMD earnings call for the period ending March 31, 2019....

Read more

Abiomed, Inc. (NASDAQ:ABMD) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 ET Company Participants Ingrid Ward - Director, IR Michael Minogue - Chairman,...

Read more

ABMD, FLR and W among premarket losers
01:13pm, Thursday, 02'nd May 2019
No summary available....

Read more

No summary available....

Read more

Abiomed (ABMD) Matches Q4 Earnings Estimates
12:25pm, Thursday, 02'nd May 2019
Abiomed (ABMD) delivered earnings and revenue surprises of 0.00% and -4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

Read more

Abiomed beats by $0.50, misses on revenue
11:05am, Thursday, 02'nd May 2019
Abiomed (ABMD): Q4 GAAP EPS of $1.60 beats by $0.50. Revenue of $207.08M (+18.7% Y/Y) misses by $11.8M. Press Release...

Read more

Abiomed (ABMD) closed the most recent trading day at $268.14, moving -1% from the previous trading session....

Read more

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

Abiomed (ABMD) closed at $256.28 in the latest trading session, marking a +1.9% move from the prior day....

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank